Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Net: 2015-2024

Historic Receivables - Net for Spyre Therapeutics (SYRE) over the last 2 years, with Dec 2024 value amounting to $5.9 million.

  • Spyre Therapeutics' Receivables - Net was N/A to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A change from last year.
  • Per Spyre Therapeutics' latest filing, its Receivables - Net stood at $5.9 million for FY2024, which was up 247.06% from $1.7 million recorded in FY2015.
  • Spyre Therapeutics' Receivables - Net's 5-year high stood at $5.9 million during FY2024, with a 5-year trough of $5.9 million in FY2024.
  • For the 1-year period, Spyre Therapeutics' Receivables - Net averaged around $5.9 million, with its median value being $5.9 million (2024).